The Food and Drug Administration (FDA) has announced an upcoming public advisory committee meeting of the Arthritis Advisory Committee. The committee will discuss new drug application (NDA) 214487, for avacopan oral capsules, submitted by ChemoCentryx, Inc., for the treatment of anti-neutrophil cytoplasmic antibody-associated vasculitis. The virtual meeting will be open to the public. For complete information, visit: